ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,487.03
      0.25%
      US Tech 100
      19,430.40
      0.14%
      Dow Jones
      38,834.86
      0.15%
      Brent Oil
      84.965
      0.21%
      Bitcoin
      65,031.92
      -0.16%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Context Therapeutics Inc (CNTX)

      7. Context Therapeutics Inc (CNTX) News

      CNTX

      Context Therapeutics (CNTX)

      Context Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:CNTX
      DateTimeSourceHeadlineSymbolCompany
      03/22/20235:10PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CNTXContext Therapeutics Inc
      03/22/20235:08PMGlobeNewswire Inc.Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline UpdatesNASDAQ:CNTXContext Therapeutics Inc
      03/15/20237:30AMGlobeNewswire Inc.Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023NASDAQ:CNTXContext Therapeutics Inc
      02/14/20235:26PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNTXContext Therapeutics Inc
      02/14/20235:26PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNTXContext Therapeutics Inc
      02/14/20235:25PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNTXContext Therapeutics Inc
      02/14/20234:05PMEdgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:CNTXContext Therapeutics Inc
      02/13/20234:04PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNTXContext Therapeutics Inc
      02/06/20234:04PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNTXContext Therapeutics Inc
      02/06/20237:30AMGlobeNewswire Inc.Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial CancerNASDAQ:CNTXContext Therapeutics Inc
      01/31/20237:30AMGlobeNewswire Inc.Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast CancerNASDAQ:CNTXContext Therapeutics Inc
      01/30/20234:05PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNTXContext Therapeutics Inc
      01/27/20234:03PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CNTXContext Therapeutics Inc
      01/23/20235:04PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNTXContext Therapeutics Inc
      01/09/20237:30AMGlobeNewswire Inc.Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive CancersNASDAQ:CNTXContext Therapeutics Inc
      01/04/20237:33AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CNTXContext Therapeutics Inc
      01/04/20237:30AMGlobeNewswire Inc.Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline MilestonesNASDAQ:CNTXContext Therapeutics Inc
      12/19/20224:23PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNTXContext Therapeutics Inc
      12/19/20224:11PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNTXContext Therapeutics Inc
      12/12/20224:16PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNTXContext Therapeutics Inc
      12/08/202211:35AMTipRanksH.C. Wainwright Sticks to Their Buy Rating for Context Therapeutics (CNTX)NASDAQ:CNTXContext Therapeutics Inc
      12/08/20227:33AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CNTXContext Therapeutics Inc
      12/08/20227:30AMGlobeNewswire Inc.Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast CancerNASDAQ:CNTXContext Therapeutics Inc
      12/02/20226:15AMTipRanksContext Therapeutics (CNTX) Receives a Buy from H.C. WainwrightNASDAQ:CNTXContext Therapeutics Inc
      12/01/20228:03AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CNTXContext Therapeutics Inc
      11/29/20227:30AMGlobeNewswire Inc.Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid TumorsNASDAQ:CNTXContext Therapeutics Inc
      11/21/20229:11AMGlobeNewswire Inc.Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer SymposiumNASDAQ:CNTXContext Therapeutics Inc
      11/14/20224:22PMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:CNTXContext Therapeutics Inc
      11/14/20226:07AMEdgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:CNTXContext Therapeutics Inc
      11/10/20226:17AMTipRanksH.C. Wainwright Remains a Buy on Context Therapeutics (CNTX)NASDAQ:CNTXContext Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:CNTX